Why I'm telling friends to avoid gold stocks

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

Julia G. Butchko net worth and biography

Julia Butchko Biography and Net Worth

Insider of Immunovant

Prior to joining Immunovant, Julia oversaw strategy and operations as Chief of Staff for the $4 billion Immunology and Neuroscience businesses at Lilly. She previously served as Vice President of Lilly’s Oncology Portfolio Management and Clinical Development teams where she was responsible for over 100 global clinical trials, including immune-oncology collaborations with Merck, Bristol-Myers Squibb, and AstraZeneca. Earlier in her career, Julia held significant roles in product development, marketing, manufacturing, and quality.

She holds a B.S. in Chemistry from the State University of New York at Fredonia, a Ph.D. in Chemistry from Pennsylvania State University, and a Business Certificate from Indiana University’s Kelley School of Business.

What is Julia G. Butchko's net worth?: The estimated net worth of Julia G. Butchko is at least $11.65 million as of July 9th, 2024. Dr. Butchko owns 446,853 shares of Immunovant stock worth more than $11,653,926 as of December 24th. This net worth approximation does not reflect any other investments that Dr. Butchko may own. Additionally, Dr. Butchko receives an annual salary of $531,000.00 as Insider at Immunovant. Learn More about Julia G. Butchko's net worth.
How old is Julia G. Butchko?: Dr. Butchko is currently 53 years old. There are 6 older executives and no younger executives at Immunovant. The oldest executive at Immunovant is Dr. William L. Macias M.D., Ph.D., Chief Medical Officer, who is 65 years old. Learn More on Julia G. Butchko's age.
What is Julia G. Butchko's salary?: As the Insider of Immunovant, Inc., Dr. Butchko earns $531,000.00 per year. There are 3 executives that earn more than Dr. Butchko. The highest earning executive at Immunovant is Dr. Peter Salzmann M.B.A., M.D., CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Julia G. Butchko's salary.
How do I contact Julia G. Butchko?: The corporate mailing address for Dr. Butchko and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Julia G. Butchko's contact information.
Has Julia G. Butchko been buying or selling shares of Immunovant?: Julia G. Butchko has not been actively trading shares of Immunovant during the past quarter. Most recently, Julia G. Butchko sold 1,527 shares of the business's stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $28.06, for a transaction totalling $42,847.62. Following the completion of the sale, the insider now directly owns 446,853 shares of the company's stock, valued at $12,538,695.18. Learn More on Julia G. Butchko's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, insiders at the sold shares 38 times. They sold a total of 226,233 shares worth more than $6,598,313.84. The most recent insider tranaction occured on November, 20th when insider Mark S Levine sold 3,650 shares worth more than $92,892.50. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 11/20/2024.

Julia G. Butchko Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/9/2024	Sell	1,527	$28.06	$42,847.62	446,853
5/22/2024	Sell	3,247	$29.65	$96,273.55	448,380
4/17/2024	Sell	10,115	$29.06	$293,941.90	451,627
4/9/2024	Sell	1,053	$31.18	$32,832.54	461,742
1/5/2024	Sell	1,297	$38.59	$50,051.23	409,963
11/22/2023	Sell	3,265	$32.78	$107,026.70	411,260
10/5/2023	Sell	1,735	$36.24	$62,876.40	414,525
7/12/2023	Sell	1,470	$19.73	$29,003.10	428,593
4/18/2023	Sell	1,544	$15.27	$23,576.88	430,063
1/11/2023	Sell	60,490	$16.79	$1,015,627.10	331,419
10/13/2022	Sell	928	$9.18	$8,519.04	391,909
9/28/2022	Sell	535	$4.67	$2,498.45	392,837
8/30/2022	Sell	548	$5.83	$3,194.84	393,372
7/27/2022	Sell	510	$4.27	$2,177.70	281,104
6/29/2022	Sell	460	$4.02	$1,849.20	281,614
5/24/2022	Sell	492	$3.79	$1,864.68	282,074
4/27/2022	Sell	541	$4.72	$2,553.52	282,566
3/24/2022	Sell	6,381	$5.90	$37,647.90	283,107
9/11/2020	Buy	5,000	$38.17	$190,850.00	5,000

Julia G. Butchko Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.08

$25.44

$26.24

50 Day Range

MA: $28.45

$25.22

$31.42

2 Week Range

Now: $26.08

$24.61

$45.58

Volume

908,488 shs

Average Volume

1,068,167 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Julia Butchko Biography and Net Worth

What is Julia G. Butchko's net worth?

How old is Julia G. Butchko?

What is Julia G. Butchko's salary?

How do I contact Julia G. Butchko?

Has Julia G. Butchko been buying or selling shares of Immunovant?

Who are Immunovant's active insiders?

Are insiders buying or selling shares of Immunovant?